Making this make-or-break mark even more notable is that investors are expecting a key ruling to be decided in J&J's role with the opioid crisis.

While some analysts are forecasting a potential fine between $500 million and $5 billion, many seem to be pricing in a figure at or below the former.

While a fine isn't good for the bottom line, the stock may still rally now that the air is cleared and an unknown event is out of the way.

After breaking below the 200-week moving average in July, the stock tested this area repeatedly for a few weeks.

If the stock's reaction to the opioid news is positive, investors will need to see the share price reclaim this moving average.

Join Jim Cramer's Action Alerts PLUS investment club to become a smarter investor!